CardioDX hires Khush Mehta as CEO

CardioDx hired Khush F. Mehta as CEO and a member of the board of directors on June 1.

Mehta joined the company from Siemens, where he served as the global head of the healthcare enterprise solutions division. He was also the chief strategy officer of Siemens Healthcare from 2010 to 2014.

Mehta succeeds David Levison, who was named the company’s chief strategy officer, where he will lead business development, health payer coverage and development of next generation technologies. Levison founded the company in 2004.

CardioDX, a privately held molecular diagnostics company, manufactures the Corus CAD blood test that provides information on the likelihood of a person having obstructive coronary artery disease. The test accounts for a person’s age, sex and gene expression and calculates a score. A higher score means a person is more likely to have a significant narrowing or blockage in the heart arteries.

CardioDX has raised $284 million in total equity funding from 25 investors, according to CrunchBase. The company raised $12.37 million in series D funding on Feb. 22, two months after Timothy Henn joined CardioDX as chief financial officer.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.